This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.
Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.
ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.
PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.
PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up
by Zacks Equity Research
Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.
IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.
NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down
by Zacks Equity Research
NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.
Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
HSIC vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. ALGN: Which Stock Is the Better Value Option?
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align, AngioDynamics and Caterpillar highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
Competition isn't even close as orthodontists are committing to the top digital platform for their patients
Anatomy of Success: Align Technology (ALGN)
by Madeleine Johnson
Here is an example that demonstrates how an investor could have used the Zacks Rank to find a stock that is just beginning to see accelerated price appreciation.
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
Top Ranked Momentum Stocks to Buy for July 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 27th:
Zacks.com highlights: Intuitive Surgical, Celanese, Great Southern Bancorp, Mellanox Technologies and Align Technology
by Zacks Equity Research
Zacks.com highlights: Intuitive Surgical, Celanese, Great Southern Bancorp, Mellanox Technologies and Align Technology
Align Technology (ALGN) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.
Stryker (SYK) Beats on Q2 Earnings, International Sales Up
by Zacks Equity Research
Stryker (SYK) gains from solid segmental performance in Q2.
Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.
Boston Scientific (BSX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q2.
5 Top-Ranked Stocks Picked via Driehaus Strategy
by Zacks Equity Research
We have used Driehaus strategy to select the top momentum stocks using the "buy high and sell higher" rule.